Chest X-ray — Radiographic Thoracic Imaging

A chest X-ray utilizes ionizing electromagnetic radiation directed through the thoracic cavity onto a digital detector plate. Tissues of varying densities attenuate the radiation beam to different extents. Dense bone absorbs the greatest proportion, appearing white; air-filled lung parenchyma absorbs minimal radiation, appearing black; and soft-tissue structures, such as the heart and blood vessels, show varying grey gradations.

Standard examinations include posteroanterior (PA) and lateral projections taken while holding a deep breath. In oncology, chest radiography is frequently utilised as an accessible first-line assessment to identify macroscopic lung lesions, mediastinal widening, consolidation, atelectasis, pneumothorax, or pleural effusions resulting from primary malignancies, metastatic spread, or therapeutic adverse reactions.

The speed and accessibility of a chest X-ray make it an indispensable everyday assessment tool throughout your cancer journey. It assists clinicians in determining baseline cardiopulmonary health before major operations or toxic treatments begin. It also serves as an immediate first evaluation whenever new symptoms develop—such as breathlessness, fever, or chest pain—allowing rapid identification of conditions like pneumonia, pulmonary fluid accumulation, or pneumothorax.

A chest X-ray is an anatomical imaging technique rather than a molecular biomarker test. However, when an X-ray identifies suspicious nodules, consolidation, or effusion, it triggers targeted follow-up diagnostic tests. These often include contrast-enhanced thoracic computed tomography (CT), positron emission tomography (PET-CT), bronchoscopy, or pleural fluid cytology to characterise histological and molecular features of the finding.

Chest X-rays are relevant across thoracic and metastatic cancers. They may detect initial abnormalities in non-small cell and small cell lung cancers, mesothelioma, and thymoma. They are also widely used during staging and routine symptom investigations for cancers prone to pulmonary metastases, including breast, colorectal, renal cell, and testicular cancers, as well as Hodgkin and non-Hodgkin lymphomas.

Detecting an abnormality on a chest X-ray can significantly influence medical plans. Uncovering an unexpected lung lesion will prompt immediate cross-sectional imaging before initiating therapy. Identifying drug-induced pneumonitis from immunotherapy or targeted inhibitors warrants temporary treatment cessation and systemic steroid administration. Similarly, detecting a large pleural effusion may require urgent therapeutic thoracentesis to alleviate dyspnoea prior to systemic therapy.